Abstract
A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have